Trisubstituted carbocyclic cyclophilin binding compounds and their use

• US 20040157919A1
• Filed: 11/14/2003
• Published: 08/12/2004
• Est. Priority Date: 01/25/2002
• Status: Abandoned Application

• Current Assignee: David Limburg, Douglas Wilkinson, Gregory S. Hamilton, Joseph P. Steiner, Mark Vaal, Sergei Belyakov, Wei Ling, Yong-Qian Wu
• Original Assignee: David Limburg, Douglas Wilkinson, Gregory S. Hamilton, Joseph P. Steiner, Mark Vaal, Sergei Belyakov, Wei Ling, Yong-Qian Wu
• Inventors: Hamilton, Gregory S., Limburg, David, Vaal, Mark, Steiner, Joseph P., Wei, Ling, Wu, Yong-Qian, Wilkinson, Douglas, Belyakov, Sergei
• Application Number:
  US10/713,566
• Publication Number:
  US 20040157919A1
• Time in Patent Office: Days
• US Class Current: 514/485
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/325 Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof thiurams A61K31/145
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.

Claims

1. A compound of the following Formula I:

2. A compound according to claim 1,

wherein V is selected from the group consisting of C₁-C₄ alkyloxy, C₂-C₄ alkenyloxy which is optionally substituted with Q, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkylcarbamoyl which is optionally substituted with amino or C₁-C₄ alkoxycarbonylamino;

di-(C₁-C₄ alkyl)carbamoyl, C₁-C₄ alkanoyl, Q-substituted C₁-C₆ straight or branched chain alkyl, alkenyl, or alkynyl, —

CO—

W, and —

(CH₂)_n—

W;

X and Y are independently;

and where Y may further be;

Q,

or C₁-C₆ straight or branched chain alkyl, alkenyl, or alkynyl which is substituted at one or several positions with Q, and which further is optionally substituted at one or several positions by hydroxyl, mercaptyl, or carbonyl oxygen;

and wherein Q is a mono-, bi-, or tricyclic, carbo- or heterocyclic ring, which is saturated, partially saturated, or aromatic, and wherein the individual ring sizes are 5-6 members, and wherein each heterocyclic ring, if present, contains 1-6 heteroatoms independently selected from the group consisting of O, N, or S in any chemically stable order and oxidation state, and wherein Q is optionally substituted in one or several positions with;

halo;

hydroxyl;

mercaptyl;

nitro;

trifluoromethyl;

acetyl;

aminocarbonyl;

arylaminocarbonyl which is optionally halogenated and optionally substituted with trifluoromethyl or cyano;

methylsulfonyl;

methylthio;

oxo;

cyano;

carboxy;

C₁-C₆ straight or branched chain alkyl or alkenyl;

C₁-C₄ alkoxy;

C₁-C₄ alkenyloxy;

phenoxy;

phenyl;

cyanophenyl;

benzyloxy;

benzyl;

amino;

C₁-C₄ alkylamino;

di-(C₁-C₄) alkylamino;

or a combination thereof.

3. A compound according to claim 1, wherein V is —

(CH₂)_n—

W, n is 0, and W is halo.

4. A compound according to claim 1, wherein V is attached at position 5.

5. The compound of claim 4, wherein V is —

(CH₂)_n—

W; and

W is -Z′

-(CH₂)_m-Q.

6. The compound of claim 5, wherein n is 1, m is 0, and Z′

is 0.

7. The compound of claim 5, wherein n is 0, m is 1, and Z′

is 0.

8. The compound of claim 5, wherein n and m are 0, and Z′

is NH.

9. The compound of claim 4, wherein V is Q-substituted C₁-C₆ straight or branched chain alkyl, or Q-substituted C₂-C₆ straight or branched chain alkenyl.

10. A compound according to claim 1, wherein n′

is 0, and X and Y are independently

11. The compound of claim 10, wherein each R is independently Q, or Q-substituted C₁-C₆ alkyl.

12. The compound of claim 11, wherein V is attached at position 5.

13. The compound of claim 12, wherein V is —

(CH₂)_n—

W;

and W is -Z′

-(CH₂)_m-Q.

14. The compound of claim 13, wherein n is 1, m is 0, and Z′

is O.

15. The compound of claim 13, wherein n is 0, m is 1, and Z′

is O.

16. The compound of claim 13, wherein n and m are 0, and Z′

is NH.

17. The compound of claim 12, wherein V is Q-substituted C₁-C₆ straight or branched chain alkyl, or Q-substituted C₂-C₆ straight or branched chain alkenyl.

18. A compound according to claim 1, wherein the compound is selected from the group consisting of

Compound 1:

3-{3,5-Bis-[3-(3,5-dichlorophenyl)-ureido]-phenyl}propionic acid methyl ester;

Compound 2;

5-Hydroxy-N,N′

-bis-(3-trifluoromethyl-phenyl)-isophthalamide;

Compound 3;

5-Naphthalen-1-yl-N,N′

-bis-(3-trifluoromethyl-phenyl)isophthalamide;

Compound 4;

(6-[3-[3-(3,5-Dichloro-phenyl)-ureido]-5-(3-trifluoromethyl-phenylcarbamoyl)-benzoylamino]hexyl]carbamic acid tert-butyl ester;

Compound 5;

3-{3,5-Bis-[3-(3,5-dichlorophenyl)ureido]-phenyl)methyl ester;

Compound 6;

1,3-(3,5-Dichlorophenyl)-N-[5-(3,4-dichlorophenoxymethyl)phenyl]amide;

Compound 7;

1,3-(1-Naphthalene)-N-[5-(3,4-dichloro-phenoxymethyl)phenyl]-sulfonamide;

Compound 8;

3,5-Di(benzyloxy)-3′

-(trifluoromethyl)benzanilid;

Compound 9;

N-(5-{[2-aza-2-(3,5-dichlorophenyl)-1-methylthiovinyl]amino}-3-{[3-(trifluoromethyl)phenyl]amino}phenyl)(3,5-dichlorophenyl) formamide;

Compound 10;

(3,5-dichlorophenyl)-N-[5-({[(3,5-dichlorophenyl)amino]thioxomethyl}amino)-3-{[3-(trifluoromethyl)phenyl]amino}phenyl]formamide;

Compound 11;

[(3,5-dichlorophenyl)amino]{[3-({[(3,5-dichlorophenyl) amino]thioxomethylamino)-5-[(4-bromophenyl)amino]phenyl]amino}methane-1-thione;

Compound 12;

N-(5-[(1,3-dioxoisoindolin-2-yl)methyl]-3-{[3-(trifluoromethyl)phenyl]carbonylamino}phenyl)[3-(trifluoromethyl) phenyl]formamide;

Compound 13;

[(3,5-dichlorophenyl)amino]{[3-({[(3,5-dichlorophenyl) amino]thioxomethyl}amino)-5-(2-pyridylamino)phenyl]amino}methane-1-thione;

Compound 14;

N-(5-{[(naphthylmethyl)amino]methyl}-3-{[3-(trifluoromethyl)phenyl]carbonyl-amino}phenyl)[3-(trifluoromethyl) phenyl]formamide;

Compound 15;

1-Benzoyl-2-{3-[(3-trifluoromethyl)phenyl]carbonylamino-5-hydroxy}benzoylhydrazine;

Compound 16;

(3-(2-(4-pyridyl)vinyl)-5-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]form amide).

Compound 16;

(3-(2-(4-pyridyl)vinyl)-5-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 17;

(5-(2-naphthyloxy)-3-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 17;

(5-(2-naphthyloxy)-3-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 18;

(5-(2-naphthyl)-3-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 18;

(5-(2-naphthyl)-3-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 19;

1-[(3,4-dichlorophenyl)oxymethyl]-3,5-bis-{[2-(3,4-dichlorophenyl)ethyl]aminocarbonyl}benzene;

Compound 20;

1-[(3,4-dichlorophenyl)oxymethyl]-3,5-bis-[(3,5-dichlorophenyl)aminocarbonyl]benzene;

Compound 21;

1-[4-(2-cyanophenyl)benzy]loxy-3,5-bis{2-[(3,4-dichlorophenyl)ethyl]aminocarbonyl}benzene;

Compound 22;

1-[4-(2-cyanophenyl)benzy]loxy-3,5-bis-[(3-cyanophenyl)aminocarbonyl]benzene;

Compound 23;

(5-(2-(2-5,6,7,8-tetrahydronaphthyl)ethyl)-3-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl) phenyl]formamide;

Compound 23;

(5-(2-(2-5,6,7,8-tetrahydronaphthyl)ethyl)-3-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl) phenyl]formamide;

Compound 24;

(5-(2-(2-naphthyl)ethyl)-3-{N-[3-(trifluoromethyl) phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 24;

(5-(2-(2-naphthyl)ethyl)-3-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 25;

(5-(2-(2-naphthyl)vinyl)-3-{N-[3-(trifluoromethyl) phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 25;

(5-(2-(2-naphthyl)vinyl)-3-{N-[3-(trifluoromethyl) phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 26;

(3-bromo-5-{N-[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-N-[3-(trifluoromethyl)phenyl]formamide;

Compound 27;

2-{[3,5-bis({[(3,5-dichlorophenyl)amino]thioxomethyl}amino)phenyl]methyl}iso-indoline-1,3-dione;

Compound 28;

1-(3,5-Dichlorophenyl)-3-[3-(3,5-dichlorobenzyloxy)-4-methoxyphenyl]urea;

Compound 29;

N-(3-{bis[(3,5-dichlorophenyl)sulfonyl]amino}-4-bromophenyl)[(3,5-dichlorophenyl)amino]formamide;

Compound 30;

Bis[(3,5-dichlorophenyl)sulfonyl](3-{bis[(3,5-dichlorophenyl)sulfonyl]amino)-4-bromophenyl)amine;

Compound 31;

2-{[3-amino-5-({[(3,5-dichlorophenyl)amino]thioxomethyl}amino)phenyl]methyl}isoindoline-1,3-dione;

Compound 32;

1-(3,4-dichlorobenzyloxy)-3,5-bis-[(3,4,5-trichlorophenyl) aminocarbonyl]benzene;

Compound 33;

[(3,5-Dichlorophenyl)amino]{[2-bromo-5-(naphthylmethoxy)phenyl]amino}methane-1-thione;

Compound 34;

N-[2-bromo-5-(naphthylmethoxy)phenyl][3-(trifluoromethyl)phenyl]formamide;

Compound 35;

[(3,5-dichlorophenyl)amino]{[5-([(3,5-dichlorophenyl) amino]thioxomethylamino)-2-{[4-(dimethylamino)phenyl]amino}phenyl]amino}methane-1-thione;

Compound 36;

[(3,5-dichlorophenyl)amino]{[3-({[(3,5-dichlorophenyl) amino]thioxo-methyl}amino)-4-[(4-chlorophenyl)amino]phenyl]amino}methane-1-thione;

Compound 37;

3-{[(3-Trifluoromethyl-4-chlorophenyl)aminocarbonyl]benzyloxy}-1,5-bis-[(3-trifluoromethyl-4-chlorophenyl)aminocarbonyl]benzene;

Compound 38;

3-{[(3,4-dichlorophenyl)aminocarbonyl]benzyloxy}-1,5-bis[(3,4-dichlorophenyl)aminocarbonyl]benzene;

Compound 39;

[(3,5-dichlorophenyl)amino]{[3-({[(3,5-dichlorophenyl) amino]thioxo-methyl}amino)-4-(3,5-dimethylpyrazolyl)phenyl]amino}methane-1-thione;

Compound 40;

[(3,5-dichlorophenyl)amino]{[3-({[(3,5-dichlorophenyl) amino]thioxomethyl}amino)-4-[(4-phenoxyphenyl)amino]phenyl]amino}methane-1-thione;

Compound 41;

{2-bromo-5-[N-(3-nitrophenyl)carbamoyl]phenyl}-N-(3-nitrophenyl)formamide;

Compound 42;

1,3-Bis[(3-trifluoromethylphenyl)aminocarbonyl]-5-[(2-naphthyl)methyloxy]benzene;

Compound 43;

1,3-Bis-[3,4-dichlorophenyl)aminocarbonyl]-5-(benzyloxy)benzene;

Compound 44;

[(3,5-dichlorophenyl)amino]{[5-({[(3,5-dichlorophenyl) amino]thioxomethylamino)-2-piperidylphenyl]amino}methane-1-thione;

Compound 45;

1-[3-(3,5-Dichlorophenoxy)methyl-4-methoxyphenyl]-3-(3,5-dichlorophenyl)thiourea;

Compound 46;

1-[3-(3,5-Dichlorophenoxy)methyl-4-methoxyphenyl]-3-benzoylthiourea;

Compound 47;

N-[4-methoxy-3-(naphthylmethoxy)phenyl]naphthylformamide;

Compound 48;

N-[4-methoxy-3-(naphthylmethoxy)phenyl]-2-naphthylethanamide;

Compound 49;

N-[4-methoxy-3-(naphthylmethoxy)phenyl]-2,2-diphenylethanamide;

Compound 50;

[4-Methoxy-3-(2-naphthylethoxy)phenyl](naphthylsulfonyl)amine;

Compound 51;

(3,5-Dichlorophenyl)-N-[4-chloro-3-(phenylcarbonyl) phenyl]formamide;

Compound 52;

(3,5-Dichlorophenyl)-N-(5-{[(diphenylmethyl)amino]sulfonyl}-2-chlorophenyl) formamide; and

Compound 53;

1-{3-[(5-Phenyl)valeroylamino]-5-bromobenzoyl}-4-(3,4-dichlorophenyl)thiosemicarbazide.

19. A pharmaceutical composition, comprising:

(i) a compound of Formula I as defined in claim 1, and

(ii) a pharmaceutically acceptable carrier, diluent, or excipient.

20. The pharmaceutical composition of claim 19, further comprising an additional agent selected from the group consisting of hair growth-promoting agents, hair loss-retarding agents, antibiotic agents, antidandruff agents, anti-inflammatory agents, pediculicides, antipruriginous agents, anaesthetic agents, keratolytic agents, antiseborrhoeic agents, antiacne agents, and hair dyes.

21. A method of using a compound to bind a cyclophilin-type immunophilin protein, comprising:

contacting the compound with a cyclophilin-type immunophilin, wherein the compound is of Formula I as defined in claim 1.

22. The method of claim 21, wherein contacting the compound with a cyclophilin-type immunophilin occurs in vitro.

23. The method of claim 21, wherein contacting the compound with a cyclophilin-type immunophilin occurs in vivo.

24. The method of claim 23, wherein contacting the compound with a cyclophilin-type immunophilin occurs after administration to an animal.

25. The method of claim 22, wherein contacting the compound with a cyclophilin-type immunophilin occurs within a cell.

26. The method of claim 22, wherein contacting the compound with a cyclophilin-type immunophilin occurs in a cell-free preparation.

27. A complex of a compound of Formula I of claim 1, and a cyclophilin-type immunophilin.

28. The complex of claim 27, wherein the cyclophilin-type immunophilin is human.

29. A method of using a compound of Formula I of claim 1, comprising:

administering a pharmaceutically effective amount of the compound to an animal.

30. The method of claim 29, wherein the animal is diagnosed with, is predisposed to, or is suspected of having a neurological disorder.

31. A method of treating a neurological disorder in a patient, comprising administering to said patient a therapeutically effective amount of a compound of Formula I of claim 1, or of a pharmaceutically acceptable derivative thereof, wherein the neurological disorder is a neurodegenerative disorder;

neuropathic disorder;

neurovascular disorder;

traumatic injury of the brain, spinal cord, or peripheral nervous system;

demyelinating disease of the central or peripheral nervous system;

metabolic or hereditary metabolic disorder of the central or peripheral nervous system;

or toxin-induced- or nutritionally related disorder of the central or peripheral nervous system.

32. The method of claim 31, wherein the neurodegenerative disorder is Parkinson'"'"'s disease, Alzheimer'"'"'s disease, amyotrophic lateral sclerosis (ALS), Huntington'"'"'s disease, cerebellar ataxia, or multisystem atrophy.

33. The method of claim 31, wherein the demyelinating disease is multiple sclerosis, Guillain-Barré

syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.

34. The method of claim 31, wherein the neurovascular disorder is global cerebral ischemia, spinal cord ischemia, ischemic stroke, cardiogenic cerebral embolism, hemorrhagic stroke, lacunar infarction, or a multiple infarct syndrome.

35. The method of claim 31, wherein the traumatic injury of the central or peripheral nervous system is concussion injury;

contusion injury;

diffuse axonal injury;

edema;

hematoma associated with craniocerebral or spinal trauma;

axonal or nerve sheath damage associated with laceration, compression, stretch, or avulsion of peripheral nerves or plexi;

or neural tissue damage caused during surgery.

36. The method of claim 35 wherein the surgery is prostate surgery, and the neural tissue damage is to the major pelvic ganglion or to the cavernous nerve.

37. The method of claim 31, wherein the neuropathic disorder is diabetic neuropathy, uremic neuropathy, neuropathy related to drug therapy, or neuropathy associated with viral infection.

38. The method of claim 31, wherein the metabolic disorder is status epilepticus, hypoglycemic coma, or Wilson'"'"'s disease.

39. A method of preventing a neurological disorder, comprising administering to an animal a pharmaceutically effective amount of a compound of Formula I of claim 1, or of a pharmaceutically acceptable derivative thereof.

40. A method of stimulating hair growth, preventing hair loss, or retarding hair loss in a mammal, comprising administering to said mammal an effective amount of a compound of Formula I of claim 1, or of a pharmaceutically acceptable derivative thereof.

41. The method of claim 40, wherein said mammal is undergoing therapy with a cancer chemotherapeutic agent.

42. The method of claim 41, wherein said cancer chemotherapeutic agent is cisplatin, carboplatin, cyclophosphamide, dactinomycin, etoposide, hexamethamelamine, ifosfamide, taxol, vincristine, bleomycin, or 5-fluorouracil.

43. The method of claim 40, wherein said mammal is undergoing radiation therapy.

44. The method of claim 40, wherein said mammal is suffering from alopecia areata, androgenetic alopecia/male pattern baldness, anagen effluvium, trichotillomania, traction alopecia, or telogen effluvium.

45. The method of claim 40, wherein said mammal is undergoing therapy with methotrexate, nonsteroidal anti-inflammatory drugs, or beta blockers.

46. A method of blocking the permeability transition pore in mitochondria, comprising:

contacting said mitochondria with a compound of Formula I of claim 1, or with a pharmaceutically acceptable derivative thereof.

47. A method of inhibiting breakdown of mitochondrial metabolism in cells which undergo oxidative stress, comprising:

contacting said cells with a compound of Formula I of claim 1, or with a pharmaceutically acceptable derivative thereof.

48. A method of preventing or delaying cell death in a cell subjected to calcium overload, comprising:

contacting said cell with a compound of Formula I of claim 1, or with a pharmaceutically acceptable derivative thereof

49. A method of preventing, mitigating, or delaying excitotoxic or hypoglycemic injury to cells, tissues, or organs, comprising:

contacting said cells, tissues, or organs with a compound of Formula I of claim 1, or with a pharmaceutically acceptable derivative thereof.

50. A method of inhibiting breakdown of energy metabolism and cell death of mammalian cells following physiological induction of programmed cell death, comprising:

contacting said cells with a compound of Formula I of claim 1, or with a pharmaceutically acceptable derivative thereof.

51. A method of preventing or delaying death of cultured cells in large scale or commercial scale cell culture, comprising:

contacting said cells with a compound of Formula I of claim 1, or with a pharmaceutically acceptable derivative thereof.

52. A method of treating or preventing ischemic injury or ischemia/reperfusion injury in a mammal, comprising administering to said mammal an effective amount of a compound of Formula I of claim 1, or of a pharmaceutically acceptable derivative thereof.

53. The method of claim 52, wherein said ischemic injury or ischemia/reperfusion injury is mesenteric infarction, bowel ischemia, hepatic infarction, renal infarction, splenic infarction, or ischemic heart disease.

54. The method of claim 53, wherein said ischemic heart disease is congestive heart failure, myocardial ischemia, or coronary heart disease.

55. A method of treating an ophthalmic disorder in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of Formula I of claim 1, or of a pharmaceutically acceptable derivative thereof.

56. The method of claim 55, wherein said ophthalmic disorder is glaucoma, ischemic retinopathy, vascular retinopathy, or degeneration of the photoreceptor cell layer.

57. A method of treating Reye'"'"'s syndrome in a patient, comprising administering to said patient a therapeutically effective amount of a compound of Formula I of claim 1, or of a pharmaceutically acceptable derivative thereof.

58. A method of preventing or reducing tissue damage of organs used in organ transplantation surgery, comprising contacting said organs with a compound of Formula I of claim 1, or with a pharmaceutically acceptable derivative thereof.

59. A method of treating an infection or infestation with pathogenic protozoan or helmintic parasites, comprising contacting said parasites with a compound of Formula I of claim 1.

60. A method of treating an infection with pathogenic protozoan or helmintic parasites in an animal, comprising administering to said animal a therapeutically effective amount of a compound of Formula I of claim 1, or with a pharmaceutically acceptable derivative thereof.

61. The method of claim 60, wherein said infection is malaria, river blindness, lymphatic filariasis, intestinal roundworm infection, tapeworm infection, pinworm infection, toxoplasmosis, leishmaniasis, trypanosomiasis, or bilharzia.

62. A method for treating a viral infection in a mammal, comprising:

administering to said mammal a therapeutically effective amount of a compound of Formula I of claim 1, or of a pharmaceutically acceptable derivative thereof.

63. The method of claim 62, wherein said viral infection is an infection with a human immunodeficiency virus.